DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

Joel N. Maslow; Ijoo Kwon; Sagar B. Kudchodkar; Deborah Kane; Amha Tadesse; Hyojin Lee; Young K. Park; Kar Muthumani; Christine C. Roberts

doi:10.3390/vaccines11061016

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

Joel N. Maslow, Ijoo Kwon, Sagar B. Kudchodkar, Deborah Kane, Amha Tadesse, Hyojin Lee, Young K. Park, Kar Muthumani, Christine C. Roberts

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.

Original language	English (US)
Article number	1016
Journal	Vaccines
Volume	11
Issue number	6
DOIs	https://doi.org/10.3390/vaccines11061016
State	Published - May 23 2023

Keywords

DNA vaccine
SARS-CoV-2
suction-mediated DNA transfection
vaccine thermostability

ASJC Scopus subject areas

Immunology
Pharmacology
Drug Discovery
Infectious Diseases
Pharmacology (medical)

Access to Document

10.3390/vaccines11061016

Cite this

@article{60e7cb55c9ce4f14820caf1773d2066a,

title = "DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond",

abstract = "We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.",

keywords = "DNA vaccine, SARS-CoV-2, suction-mediated DNA transfection, vaccine thermostability",

author = "Maslow, {Joel N.} and Ijoo Kwon and Kudchodkar, {Sagar B.} and Deborah Kane and Amha Tadesse and Hyojin Lee and Park, {Young K.} and Kar Muthumani and Roberts, {Christine C.}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = may,

day = "23",

doi = "10.3390/vaccines11061016",

language = "English (US)",

volume = "11",

journal = "Vaccines",

issn = "2076-393X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

TY - JOUR

T1 - DNA Vaccines for Epidemic Preparedness

T2 - SARS-CoV-2 and Beyond

AU - Maslow, Joel N.

AU - Kwon, Ijoo

AU - Kudchodkar, Sagar B.

AU - Kane, Deborah

AU - Tadesse, Amha

AU - Lee, Hyojin

AU - Park, Young K.

AU - Muthumani, Kar

AU - Roberts, Christine C.

PY - 2023/5/23

Y1 - 2023/5/23

N2 - We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.

AB - We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.

KW - DNA vaccine

KW - SARS-CoV-2

KW - suction-mediated DNA transfection

KW - vaccine thermostability

UR - http://www.scopus.com/inward/record.url?scp=85163589688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163589688&partnerID=8YFLogxK

U2 - 10.3390/vaccines11061016

DO - 10.3390/vaccines11061016

M3 - Article

C2 - 37376404

AN - SCOPUS:85163589688

SN - 2076-393X

VL - 11

JO - Vaccines

JF - Vaccines

IS - 6

M1 - 1016

ER -

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this